{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:16:17Z","timestamp":1792077377012,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["Intramural funding"],"award-info":[{"award-number":["Intramural funding"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI153390"],"award-info":[{"award-number":["K23AI153390"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV) remains the leading cause of hospitalization in young children. A bivalent pre-fusion (preF) protein RSV vaccine was licensed for pregnant persons in 2023 (Abrysvo, Pfizer), but the impact of RSV maternal immunization on maternal-fetal immunity has not been well characterized. We analyze neutralizing antibody responses, binding antibodies, and antibody affinity maturation in 58 unvaccinated and 49 vaccinated pregnant individuals and their infants. Maternal RSV vaccination induces robust neutralizing antibodies against both RSV-A2 and RSV-B1 strains, with geometric mean titers 8-fold and 13.4-fold higher, respectively, in vaccinated versus unvaccinated participants. Vaccination significantly enhances binding antibodies to RSV-preF protein (5.2-fold higher) and antibody affinity maturation (3.7-fold higher). High-quality RSV-specific antibodies are efficiently transferred across the placenta. However, early preterm infants showed reduced antibody transfer efficiency compared with full-term infants. These findings demonstrate that maternal RSV vaccination generates high-quality, affinity-matured transferable antibodies that provide passive immunity to infants.<\/jats:p>","DOI":"10.1038\/s41467-026-72659-3","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:44:34Z","timestamp":1778237074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9656-8976","authenticated-orcid":false,"given":"Dongxiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Posadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Mire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-4178","authenticated-orcid":false,"given":"Janet A.","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Kachikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-7965","authenticated-orcid":false,"given":"Surender","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"72659_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390, 946\u2013958 (2017).","journal-title":"Lancet"},{"key":"72659_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall, C. B. et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360, 588\u2013598 (2009).","journal-title":"N. Engl. J. Med."},{"key":"72659_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28950","volume":"6","author":"N Halasa","year":"2023","unstructured":"Halasa, N. et al. Infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak. JAMA Netw. Open 6, e2328950 (2023).","journal-title":"JAMA Netw. Open"},{"key":"72659_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113\u20131117 (2013).","journal-title":"Science"},{"key":"72659_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422\u2013434 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"72659_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"72659_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade0424","volume":"14","author":"LA Chang","year":"2022","unstructured":"Chang, L. A. et al. A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine. Sci. Transl. Med. 14, eade0424 (2022).","journal-title":"Sci. Transl. Med."},{"key":"72659_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715\u2013725 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"72659_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2020.01282","volume":"11","author":"B Abu-Raya","year":"2020","unstructured":"Abu-Raya, B. et al. Global perspectives on immunization during pregnancy and priorities for future research and development: an international consensus statement. Front. Immunol. 11, 1282 (2020).","journal-title":"Front. Immunol."},{"key":"72659_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451\u20131464 (2023).","journal-title":"N. Engl. J. Med."},{"key":"72659_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1908380","volume":"383","author":"SA Madhi","year":"2020","unstructured":"Madhi, S. A. et al. Respiratory syncytial virus Vaccination during pregnancy and effects in infants. N. Engl. J. Med. 383, 426\u2013439 (2020).","journal-title":"N. Engl. J. Med."},{"key":"72659_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","volume":"72","author":"KE Fleming-Dutra","year":"2023","unstructured":"Fleming-Dutra, K. E. et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb. Mortal. Wkly Rep. 72, 1115\u20131122 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"72659_CR13","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","volume":"386","author":"EAF Simoes","year":"2022","unstructured":"Simoes, E. A. F. et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N. Engl. J. Med. 386, 1615\u20131626 (2022).","journal-title":"N. Engl. J. Med."},{"key":"72659_CR14","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.1073\/pnas.84.16.5625","volume":"84","author":"PR Johnson","year":"1987","unstructured":"Johnson, P. R., Spriggs, M. K., Olmsted, R. A. & Collins, P. L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 84, 5625\u20135629 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72659_CR15","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","volume":"368","author":"MO Blanken","year":"2013","unstructured":"Blanken, M. O. et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N. Engl. J. Med. 368, 1791\u20131799 (2013).","journal-title":"N. Engl. J. Med."},{"key":"72659_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/2101070a0","volume":"210","author":"PF Kohler","year":"1966","unstructured":"Kohler, P. F. & Farr, R. S. Elevation of cord over maternal IgG immunoglobulin: evidence for an active placental IgG transport. Nature 210, 1070\u20131071 (1966).","journal-title":"Nature"},{"key":"72659_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae723","volume":"12","author":"KE Rumfelt","year":"2025","unstructured":"Rumfelt, K. E. et al. Maternal-Infant Respiratory Syncytial Virus and Influenza A Virus Antibody Transfer in Preterm and Full-term Infants. Open Forum Infect. Dis. 12, ofae723 (2025).","journal-title":"Open Forum Infect. Dis."},{"key":"72659_CR18","first-page":"543","volume":"140","author":"WP Glezen","year":"1986","unstructured":"Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child 140, 543\u2013546 (1986).","journal-title":"Am. J. Dis. Child"},{"key":"72659_CR19","doi-asserted-by":"publisher","first-page":"985646","DOI":"10.1155\/2012\/985646","volume":"2012","author":"P Palmeira","year":"2012","unstructured":"Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A. & Carneiro-Sampaio, M. IgG placental transfer in healthy and pathological pregnancies. Clin. Dev. Immunol. 2012, 985646 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"72659_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae314","volume":"11","author":"AB Kachikis","year":"2024","unstructured":"Kachikis, A. B. et al. Transfer of Respiratory Syncytial Virus Prefusion F Protein Antibody in Low Birthweight Infants. Open Forum Infect. Dis. 11, ofae314 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"72659_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2352-4642(25)00155-5","volume":"9","author":"TC Williams","year":"2025","unstructured":"Williams, T. C. et al. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. Lancet Child Adolesc. Health 9, 655\u2013662 (2025).","journal-title":"Lancet Child Adolesc. Health"},{"key":"72659_CR22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","volume":"359","author":"K Zaman","year":"2008","unstructured":"Zaman, K. et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl. J. Med. 359, 1555\u20131564 (2008).","journal-title":"N. Engl. J. Med."},{"key":"72659_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/infdis\/jiz608","volume":"221","author":"S Fuentes","year":"2020","unstructured":"Fuentes, S. et al. Antigenic fingerprinting of respiratory syncytial virus (RSV)-A-infected hematopoietic cell transplant recipients reveals importance of mucosal anti-RSV G antibodies in control of RSV infection in humans. J. Infect. Dis. 221, 636\u2013646 (2020).","journal-title":"J. Infect. Dis."},{"key":"72659_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.immuni.2018.01.005","volume":"48","author":"E Goodwin","year":"2018","unstructured":"Goodwin, E. et al. Infants infected with respiratory syncytial virus generate potent neutralizing antibodies that lack somatic hypermutation. Immunity 48, 339\u2013349 (2018).","journal-title":"Immunity"},{"key":"72659_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nri3804","volume":"15","author":"NS De Silva","year":"2015","unstructured":"De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137\u2013148 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"72659_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32298-w","volume":"13","author":"L Bellusci","year":"2022","unstructured":"Bellusci, L. et al. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Nat. Commun. 13, 4617 (2022).","journal-title":"Nat. Commun."},{"key":"72659_CR27","doi-asserted-by":"publisher","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","volume":"3","author":"S Khurana","year":"2011","unstructured":"Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).","journal-title":"Sci. Transl. Med."},{"key":"72659_CR28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41590-021-01051-8","volume":"22","author":"S Ravichandran","year":"2021","unstructured":"Ravichandran, S. et al. SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. Nat. Immunol. 22, 1452\u20131464 (2021).","journal-title":"Nat. Immunol."},{"key":"72659_CR29","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.1016\/j.vaccine.2014.09.049","volume":"32","author":"S Khurana","year":"2014","unstructured":"Khurana, S. et al. H5 N-terminal beta sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine. Vaccine 32, 6421\u20136432 (2014).","journal-title":"Vaccine"},{"key":"72659_CR30","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1128\/JVI.01596-12","volume":"86","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies. J. Virol. 86, 12283\u201312293 (2012).","journal-title":"J. Virol."},{"key":"72659_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09914-3","volume":"10","author":"S Ravichandran","year":"2019","unstructured":"Ravichandran, S. et al. Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome. Nat. Commun. 10, 1943 (2019).","journal-title":"Nat. Commun."},{"key":"72659_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.chom.2020.01.001","volume":"27","author":"S Khurana","year":"2020","unstructured":"Khurana, S. et al. Longitudinal human antibody repertoire against complete viral proteome from Ebola virus survivor reveals protective sites for vaccine design. Cell Host Microbe 27, 262\u2013276 (2020).","journal-title":"Cell Host Microbe"},{"key":"72659_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","volume":"7","author":"RT Davey Jr.","year":"2019","unstructured":"Davey, R. T. Jr. et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir. Med. 7, 951\u2013963 (2019).","journal-title":"Lancet Respir. Med."},{"key":"72659_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21463-2","volume":"12","author":"J Tang","year":"2021","unstructured":"Tang, J. et al. Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. Nat. Commun. 12, 1221 (2021).","journal-title":"Nat. Commun."},{"key":"72659_CR35","doi-asserted-by":"publisher","unstructured":"Ravichandran, S. et al. Longitudinal antibody repertoire in \u201cmild\u201d versus \u201csevere\u201d COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci. Adv. 7, https:\/\/doi.org\/10.1126\/sciadv.abf2467 (2021).","DOI":"10.1126\/sciadv.abf2467"},{"key":"72659_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/INF.0000000000000486","volume":"34","author":"CM Healy","year":"2015","unstructured":"Healy, C. M., Rench, M. A., Wootton, S. H. & Castagnini, L. A. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr. Infect. Dis. J. 34, 22\u201326 (2015).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"72659_CR37","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1016\/j.vaccine.2013.05.088","volume":"31","author":"S Fuentes","year":"2013","unstructured":"Fuentes, S. et al. Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. Vaccine 31, 3987\u20133994 (2013).","journal-title":"Vaccine"},{"key":"72659_CR38","doi-asserted-by":"publisher","first-page":"8193","DOI":"10.1128\/JVI.00133-15","volume":"89","author":"S Fuentes","year":"2015","unstructured":"Fuentes, S., Coyle, E. M., Golding, H. & Khurana, S. Nonglycosylated G-protein vaccine protects against homologous and heterologous respiratory syncytial virus (RSV) challenge, while glycosylated G enhances RSV lung pathology and cytokine levels. J. Virol. 89, 8193\u20138205 (2015).","journal-title":"J. Virol."},{"key":"72659_CR39","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1016\/j.vaccine.2018.10.087","volume":"36","author":"JU McDonald","year":"2018","unstructured":"McDonald, J. U., Rigsby, P., Dougall, T., Engelhardt, O. G. & Study, P. Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study. Vaccine 36, 7641\u20137649 (2018).","journal-title":"Vaccine"},{"key":"72659_CR40","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.vaccine.2019.10.095","volume":"38","author":"JU McDonald","year":"2020","unstructured":"McDonald, J. U., Rigsby, P., Atkinson, E., Engelhardt, O. G. & Study, P. Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study. Vaccine 38, 800\u2013807 (2020).","journal-title":"Vaccine"},{"key":"72659_CR41","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/nm.4201","volume":"22","author":"S Khurana","year":"2016","unstructured":"Khurana, S. et al. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat. Med. 22, 1439\u20131447 (2016).","journal-title":"Nat. Med."},{"key":"72659_CR42","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1038\/s41591-024-03189-y","volume":"30","author":"S Khurana","year":"2024","unstructured":"Khurana, S. et al. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nat. Med. 30, 2771\u20132776 (2024).","journal-title":"Nat. Med."},{"key":"72659_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11296-5","volume":"10","author":"S Khurana","year":"2019","unstructured":"Khurana, S. et al. Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. Nat. Commun. 10, 3338 (2019).","journal-title":"Nat. Commun."},{"key":"72659_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51021-5","volume":"15","author":"S Khurana","year":"2024","unstructured":"Khurana, S. et al. Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design. Nat. Commun. 15, 8133 (2024).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72659-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:01:27Z","timestamp":1784077287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72659-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72659"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72659-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kachikis reports on being a co-investigator on studies funded by Merck and Pfizer. Dr. Englund reported receiving grants\/consultant fees from AstraZeneca, GSK, Merck, Meissa vaccines, Moderna, Pfizer, Shionogi, and Cidarra (DSMB). The rest of the authors have declared that no competing interests exist.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6223"}}